Sabuwar nasarar maganin cutar kansar huhu 2020

A cikin 2020, an sami ci gaba mai mahimmanci a cikin maganin kansar huhu, gami da yarda don sabbin hanyoyin kwantar da hankali da rigakafin rigakafi, suna ba da ingantattun sakamako da hanyoyin keɓance ga marasa lafiya. Waɗannan nasarorin sun ba da sabbin zaɓuɓɓuka ga waɗanda ke fama da cutar kansar huhu, suna magance takamaiman maye gurbi da haɓaka garkuwar jiki don yaƙar cutar. Shekarar Ci gaba: Maɓalli. Sabuwar Ciwon Kankara ta Huhu 2020Shekarar 2020 ta nuna muhimmiyar shekara a cikin yaƙi da cutar kansar huhu. Yayin da cutar ta mamaye shekara ta duniya, masu bincike da likitocin sun ci gaba da tura iyakokin zaɓuɓɓukan magani. Abubuwan ci gaba masu ban sha'awa da yawa sun bayyana, suna ba da bege ga marasa lafiya da sake fasalin yanayin kula da cutar kansar huhu. Cibiyar Nazarin Ciwon Kankara ta Shandong Baofa tana bin waɗannan ci gaba a hankali.Tsarin Magunguna: Madaidaicin Magani Ci Gaban Ƙirarrun hanyoyin kwantar da hankali, waɗanda aka tsara don kai hari kan takamaiman rauni a cikin ƙwayoyin cutar kansa, sun sami babban ci gaba a cikin 2020. Waɗannan hanyoyin kwantar da hankali galibi suna haifar da ƙarancin sakamako masu illa fiye da chemotherapy na gargajiya saboda suna kai hari kan ƙwayoyin kansa daidai gwargwado.New Approvals for EGFR factors are common receptor mutations (EGFR factors). ciwon huhu mara ƙanƙanta (NSCLC). A cikin 2020, sabbin masu hanawa na EGFR an yarda da su, suna ba da ingantacciyar rayuwa marar ci gaba ga marasa lafiya tare da waɗannan maye gurbi. Waɗannan sababbin masu hanawa sukan shawo kan hanyoyin juriya waɗanda ke iyakance tasirin magungunan farko. Musamman, wakilai masu niyya EGFR exon 20 maye gurbi sun nuna ayyuka masu ban sha'awa. Misali, ɗayan irin wannan wakili shine amivantamab. Tebu mai zuwa yana nuna sakamakon gwajin asibiti na amivantamab: Matsayin Amsa Gabaɗaya na Gwaji (ORR) Tsawon Amsa (DoR) Mataki na I 40% 11.1 watanni Source: FDAMasu hana ALK: Fadada Zaɓuɓɓukan JiyyaAnaplastic lymphoma kinase (ALK) sake tsarawa wani maye gurbin direba ne a cikin NSCLC. An riga an sami masu hana ALK da yawa, kuma a cikin 2020, bincike ya mayar da hankali kan shawo kan juriya ga waɗannan magunguna da haɓaka ƙarin masu hanawa. An kuma bincika sabbin hanyoyin haɗin gwiwa don inganta sakamako a cikin ALK-tabbataccen ciwon daji na huhu.Immunotherapy: Harnessing the Power of Immune SystemImmunotherapy, wanda ke ƙarfafa tsarin garkuwar jiki don yaƙar ciwon daji, ya ci gaba da kasancewa babban yanki na ci gaba a cikin maganin ciwon huhu na huhu a cikin 2020. Masu hana masu hanawa a farkon matakaiCheckpoint sun sake dawo da masu hanawa, kamar yadda masu hanawa suka sake dawo da su. maganin ciwon daji na huhu da ya ci gaba. A cikin 2020, binciken ya bincika amfani da waɗannan magunguna a farkon matakan cutar, gami da bayan tiyata ko a hade tare da chemotherapy. Wadannan nazarin sun nuna cewa immunotherapy na iya inganta yawan rayuwa da kuma rage haɗarin sake dawowa a wasu marasa lafiya.Haɗin Immunotherapy RegimensResearchers sun kuma bincika hada magungunan rigakafi daban-daban don inganta tasirin su. Katange wuraren bincike guda biyu, ta yin amfani da nau'ikan nau'ikan nau'ikan masu hana shinge na rigakafi guda biyu, sun nuna alƙawarin a wasu marasa lafiya waɗanda ba su amsa maganin rigakafi guda ɗaya ba. Gwaje-gwaje na asibiti sun ci gaba da tsaftace waɗannan hanyoyin haɗin gwiwar don gano marasa lafiya da suka fi dacewa su amfana. Matsayin Gwajin BiomarkerCi gaban da aka yi a cikin hanyoyin kwantar da hankali da kuma maganin rigakafi sun nuna mahimmancin gwajin gwajin kwayoyin halitta a cikin ciwon huhu. A cikin 2020, an ƙara ba da fifiko kan gwaji don ɗimbin sauye-sauye na maye gurbi da kuma magana ta PD-L1 don jagorantar yanke shawarar jiyya. Wannan tsarin da aka keɓance yana tabbatar da cewa marasa lafiya sun sami mafi dacewa kuma mafi inganci don maganin ciwon daji na musamman.Shandong Baofa Cibiyar Nazarin Ciwon daji ta jaddada mahimmancin gwaji mai mahimmanci don cimma sakamako mafi kyau.Looking Ahead: Future DirectionsThe Sabbin nasarar maganin kansar huhu 2020 ya share fagen samun karin ci gaba a shekaru masu zuwa. Bincike mai gudana yana mai da hankali kan haɓaka sabbin hanyoyin kwantar da hankali, inganta dabarun rigakafin rigakafi, da gano sabbin alamomin halittu. Maƙasudin maƙasudin shine haɓaka ƙarin ingantattun jiyya da keɓancewa waɗanda ke haɓaka ƙimar rayuwa da ingancin rayuwa ga duk masu fama da cutar kansar huhu.Kammala2020 shekara ce ta ci gaba mai mahimmanci a cikin maganin cutar kansar huhu. Amincewa da sabbin hanyoyin kwantar da hankali da rigakafin rigakafi, tare da ƙarin girmamawa akan gwajin biomarker, sun canza yanayin kula da cutar kansar huhu. Waɗannan nasarorin suna ba da bege ga marasa lafiya da danginsu kuma suna nuna mahimmancin ci gaba da bincike da ƙirƙira a cikin yaƙi da wannan mummunar cuta. Yi la'akari da ziyartar Shandong Baofa Cibiyar Nazarin Ciwon daji gidan yanar gizon don ƙarin bayani kan gwaji na asibiti da ci-gaban jiyya na cutar kansa.